Free Trial

Picton Mahoney Asset Management Purchases 16,198 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Exelixis logo with Medical background

Picton Mahoney Asset Management raised its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 37,669.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,241 shares of the biotechnology company's stock after buying an additional 16,198 shares during the period. Picton Mahoney Asset Management's holdings in Exelixis were worth $599,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Coppell Advisory Solutions LLC acquired a new stake in shares of Exelixis in the 4th quarter valued at about $25,000. Colonial Trust Co SC increased its stake in Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after buying an additional 765 shares during the last quarter. Bartlett & CO. Wealth Management LLC bought a new stake in Exelixis during the 1st quarter worth about $37,000. Hurley Capital LLC acquired a new position in Exelixis during the fourth quarter valued at approximately $68,000. Finally, True Wealth Design LLC increased its position in shares of Exelixis by 222.3% during the 4th quarter. True Wealth Design LLC now owns 2,253 shares of the biotechnology company's stock worth $75,000 after purchasing an additional 1,554 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Price Performance

Shares of NASDAQ:EXEL traded down $0.40 during midday trading on Monday, reaching $36.86. 1,473,371 shares of the company's stock were exchanged, compared to its average volume of 3,081,059. Exelixis, Inc. has a fifty-two week low of $23.21 and a fifty-two week high of $49.62. The firm's 50 day simple moving average is $42.93 and its two-hundred day simple moving average is $38.93. The stock has a market cap of $9.92 billion, a price-to-earnings ratio of 17.64, a P/E/G ratio of 0.77 and a beta of 0.29.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. During the same quarter in the prior year, the firm posted $0.84 earnings per share. Exelixis's revenue for the quarter was down 10.8% on a year-over-year basis. Equities research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on EXEL shares. Jefferies Financial Group set a $50.00 price target on Exelixis and gave the company a "buy" rating in a report on Tuesday, June 24th. HC Wainwright raised their price objective on shares of Exelixis from $47.00 to $53.00 and gave the company a "buy" rating in a report on Monday, June 30th. JMP Securities reaffirmed a "market outperform" rating and set a $50.00 price target on shares of Exelixis in a research report on Tuesday, July 29th. UBS Group set a $38.00 price objective on shares of Exelixis and gave the stock a "neutral" rating in a research report on Wednesday, July 30th. Finally, Stephens upgraded Exelixis from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $29.00 to $60.00 in a report on Tuesday, June 24th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, Exelixis currently has a consensus rating of "Moderate Buy" and an average price target of $44.44.

Read Our Latest Research Report on EXEL

Insider Activity at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 126,383 shares of the business's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the transaction, the executive vice president owned 446,459 shares in the company, valued at $21,412,173.64. The trade was a 22.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Amy C. Peterson sold 72,776 shares of the company's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the completion of the sale, the chief marketing officer owned 465,393 shares in the company, valued at approximately $21,161,419.71. This trade represents a 13.52% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 456,605 shares of company stock worth $20,966,005. Company insiders own 2.82% of the company's stock.

Exelixis Profile

(Free Report)

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

See Also

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Should You Invest $1,000 in Exelixis Right Now?

Before you consider Exelixis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.

While Exelixis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without
Palantir & AMD Earnings: Massive Options Setups Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines